SCN1A rs6732655A/T polymorphism: Diagnostic and therapeutic insights for drug-resistant epilepsy

Figure 1 Restriction fragment length polymorphism-polymerase chain reaction for rs6732655A/T polymorphism. A: Amplified products electrophoresed on 2% agarose gel, 250 bp amplicons obtained; B: TaqI-digested products electrophoresed on 3% agarose gel [Lanes 1 to 8 from left to right: Lane 1: 100 bp DNA ladder; Lane 5: Homozygous wild genotype (250 bp); Lanes 2 and 7: Heterozygous mutant genotypes (250, 155 and 95 bp); Lanes 3, 4, 6 and 8: Homozygous mutant genotypes (155 and 95 bp)].

Figure 2 Receiver operating characteristic analysis of serum interleukin-1β and interleukin-6 levels between drug resistant and drug responsive groups. A: Interleukin-1β; B: Interleukin-6. ROC: Receiver operating characteristic.